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Pituitary adenylate cyclase activating polypeptide (PACAP) is involved in development and reproduc-
tion. We previously described elevated PACAP levels in the milk compared to the plasma, and the
presence of its specific PAC1 receptor in the mammary gland. This study aimed to determine PACAP
and vasoactive intestinal peptide (VIP) levels in female suckling lambs compared to ewe plasma and
mammary gland, as well as their age-dependent alterations. mRNA expressions of PACAP, VIP, PAC1
receptor and brain-derived neurotrophic factor (BDNF) were quantified in the milk whey and mammary
gland. PACAP38-like immunoreactivity (PACAP38-LI) was measured in plasma, milk whey and
mammary gland by radioimmunoassay, VIP-LI by enzyme-linked immunoassay. PACAP38-LI was 5, 6pCorresponding author. Department of Pharmacology and Pharmacotherapy, University of Pecs Medical School,
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Physiology International 107 (2020) 1, 92–105 93times higher in the milk compared to the plasma of lactating sheep. It significantly increased in the lamb
plasma 1 h, but returned to basal level 2 h after suckling. However, VIP mRNA was not present in the
mammary gland, we detected the VIP protein in the milk whey. BDNF mRNA significantly decreased
with age to approximately 60% and 25% in the 3- and 10-year-old sheep respectively, compared to the 3-
month-old lambs. No differences were found between mammary and jugular vein plasma PACAP and
VIP concentrations, or during the daily cycle. We propose a rapid absorption of PACAP38 from the milk
and/or its release in suckling lambs. PACAP accumulated in the milk might be synthesized in the
mammary gland or secreted from the plasma of the mothers. PACAP is suggested to have differentiation/
proliferation promoting and immunomodulatory effects in the newborns and/or a local function in the
mammary gland.
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Pituitary adenylate cyclase activating polypeptide (PACAP) was first isolated from ovine hy-
pothalamic extracts. Based on the structural homology (68%) of its N-terminal amino acid
sequence with the vasoactive intestinal peptide (VIP) it is considered to belong to the VIP/
glucagon/secretin family [1]. PACAP exists in two biologically active forms, PACAP27 and
PACAP38, alternatively processed from the same precursor, with PACAP38 being the dominant
form in mammals [2]. Although PACAP has poor metabolic stability and short plasma elimi-
nation half-life, it exerts important biological activities [3,4]. Since its discovery, PACAP has
been described in peripheral organs throughout the body and its effects are mediated by specific
receptors on the target cells: the PACAP-preferring PAC1 receptor and two VIP-shared VPAC1
and VPAC2 receptors [5].
Several factors influence milk composition, such as animal species, breed, feeding and
environment. It contains – among others – high levels of various proteins, vitamins, hormones
and growth factors, antimicrobial substances and immunoglobulins, which play important roles
in neonatal development and lactation [6]. Some growth factors are transferred from plasma
without any modification regarding activity and structure. Others are synthesized in the
mammary gland, such as epidermal growth factor, insulin-like growth factor, prolactin and
gonadotropin-releasing hormone [7]. Sheep and goat milk contain particularly high-quality
proteins and bioactive compounds, such as cytokines, growth factors, peptides and hormones
[6], nucleotides and ribonucleosides [8]. We have previously described the presence of
PACAP38 in the milk of various domestic animals (sheep, goat and cow) and humans, where we
found significantly elevated PACAP concentrations in the colostrum samples compared to
transitional and mature milk [9–11]. PACAP is present in the milk whey of small ruminants at
concentrations 5–20 times higher than in the plasma, and does not change during the first 3
months of lactation [11]. It is proposed that PACAP acts on the infant intestinal tract directly
and after being transferred to the circulation, it might influences organ development. Moreover,Unauthenticated | Downloaded 09/27/20 10:03 AM UTC
94 Physiology International 107 (2020) 1, 92–105PACAP can also affect development, growth and hormonal activity of the mammary gland itself
and it might have a protective action on aging-related processes [9,11,12].
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family described
in the development and survival of neuronal cells. A link between PACAP and BDNF has been
described in the central nervous system (CNS, [13]). A recent article reports the presence and
lactation-dependent alterations of BDNF in the sheep mammary gland [14]. The author suggests
that the presence of BDNF acts as a paracrine/autocrine signal responsible for crosstalk between
hormonal stimulation and the local micro environment. Since the observed correlation between
BDNF and lactation appeared to be interesting, we investigated how BDNF expression in the
sheep mammary gland changes with aging in parallel with PACAP levels.
In the present study our aims were to determine the alterations of PACAP in comparison
with the related peptide VIP 1) in the plasma of lambs in a time-dependent manner after
suckling; 2) in the plasma related to age; 3) in the milk in comparison with the respective plasma
value and during the daily cycle. Furthermore, we also examined the expression of PACAP, VIP,
their receptors and BDNF by studying their mRNAs in the mammary gland.MATERIALS AND METHODS
Animals and sample collection
Samples were collected from Hungarian Tsigai sheep according to a protocol approved by the
Institutional Ethic Committee (license number: 28/2012 DE MAB). Animals were kept in a
stable during winter and were grazing from April. Plasma and milk samples of ewes and lambs
were collected from sheep kept at an experimental farm of the University of Debrecen. The
slaughtered animals were kept at a private sheep farm, “Balmazujvaros, Hungary”. Samples were
collected under calm circumstances in a standardized manner, causing minimal distress for the
animals.
Plasma samples
After local disinfection of the skin surface, plasma samples were collected into ice-cold evacuated
plastic plasma collection tubes (Vacutainer®, BD Life Sciences, Franklin Lakes NJ USA) con-
taining the anticoagulant ethylenediaminetetraacetic acid (EDTA, 18 mg, Sigma Aldrich, St
Louis MO USA) and the peptidase inhibitor aprotinin 1.4 mg aprotinin/1 mL distilled water;
20 mL solution/1 mL plasma sample (Sigma–Aldrich, St Louis MO USA). After centrifugation
(6003 g for 10 min and 950 g for 10 min at 4 8C) plasma was removed and stored at 80 8C for
further investigations. For the suckling-related measurements, 10 mL plasma samples were
taken from the jugular vein by the same method from 3-month-old female suckling lambs
(n 5 9) before (0 h) and 1 and 2 h after suckling (1 h, 2 h). In addition, samples were also taken
from the jugular and mammary veins of their 3-year-old mothers (n 5 8), representing systemic
venous plasma and that directly from the mammary gland vein, respectively.
Milk samples
In general, milk samples (5 mL/animal) of lactating ewes were harvested in the morning into ice-
cold centrifuge tubes. To evaluate daily changes of PACAP38-like immunoreactivityUnauthenticated | Downloaded 09/27/20 10:03 AM UTC
Physiology International 107 (2020) 1, 92–105 95(PACAP38-LI) in milk whey, we collected milk samples from 4 lactating ewes (5 mL/animal), at
6 different time points (0:00, 04:00, 08:00, 12:00, 16:00 and 20:00).Slaughtering
Animals were slaughtered following a conventional procedure according to EU regulations
(Council Regulation (EC) No 1099/2009 of 24 September 2009) on the protection of animals at
the time of slaughter. Briefly, sheep providing tissue samples were stunned on the forehead with
a captive bolt pistol followed by incision of blood vessels immediately. Prior to stunning a sheep,
the other animals involved in the experiment were separated to exclude the possibility of viewing
the slaughter procedure. Ten milliliters blood, 1 cm3 mammary gland (from the glandular
component of the mammary gland) and uterus samples (as positive controls for VIP mRNA
expression) were harvested from 3-month-old (±2 weeks), 3-year-old (±4 months) and 10-year-
old (±1 year) animals (n5 4/group) immediately after slaughtering. One part of each mammary
gland and uterus sample was placed into RNA-later (Sigma–Aldrich, St Louis MO USA) for
qPCR analysis. The other parts of these samples were immediately deep frozen at 80 8C for
radioimmunoassay (RIA) and enzyme-linked immunoassay (ELISA) measurements of the
peptides.RIA measurements
PACAP38-LI in the plasma, milk and mammary gland was determined with a sensitive
PACAP38-specific RIA technique developed in our laboratory and concentrations of the peptide
were calculated with the help of a calibration curve [15, 16]. The ‘‘ab35342’’ (Abcam, Cam-
bridge, UK) PACAP38 antiserum was raised in sheep against the synthetic peptide (human)
conjugated to keyhole limpet hemocyanin. The antiserum used in the RIA is C-terminal specific,
without affinity for other members of the VIP/secretin/glucagon peptide family. The average
ID50 value was 48.6 ± 3.4 fmol/mL determined in 10 consecutive assays. Synthetic peptides were
used as RIA standard ranging from 8 to 2,000 fmol/mL. Intra-assay and inter-assay coefficients
of variation were 8.2% and 12.3%, respectively.
Protein content of a 2 mL plasma sample was extracted with the mixture of 3 mL absolute
ethanol and 10 mL 96% acetic acid. Tubes were incubated at room temperature (RT) for 20 min,
followed by centrifugation at 950 3 g at 4 8C for 20 min. The supernatant was collected into a
reaction tube and dried under nitrogen-flow at room temperature for 6 h. The dried supernatant
was suspended in 300 mL RIA buffer (previously described in detail: 16), and then centrifuged at
10,000 3 g for 15 min. One reaction tube contained 450 mL suspended dry plasma sample or
100 mL mono-125I-labeled PACAP24-38 C-terminal fragment as tracer (3,000 cpm/tube), 100 mL
antiserum (working dilution of 1:10,000), and 350 mL RIA assay buffer. After 48 h incubation at
4 8C, the antibody-bound peptide was separated from the free one by the addition of 100 mL
separating solution (content described previously in: 15). Samples were centrifuged at 950 3 g
for 20 min at 4 8C, tubes were gently decanted and the radioactivity was measured by a gamma
counter (Gamma, type: NZ310). The detection range of PACAP38-LI for the plasma samples
was between 16 and 1000 fmol/mL. The RIA procedures were the same in the case of the milk
whey and mammary gland homogenates, only sample preparation steps were different as
described below.Unauthenticated | Downloaded 09/27/20 10:03 AM UTC
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water bath for 5 min to precipitate the protein content. Samples were then centrifuged at 10
8C, 950 3 g for 10 min at 4 8C to obtain a solid fat component from the top of the samples.
The whey localized between fat and the precipitated protein fraction was removed for RIA
analysis. The detectable amount of PACAP in milk whey ranged from 125 to 2000 fmol/mL.
Mammary gland tissue samples (280 mg) were homogenized in 2 mL distilled water con-
taining a protease inhibitor cocktail (Sigma–Aldrich, St. Louis, MO, USA) using a tissue
homogenizer (MICCRA D-15), then samples were centrifuged at 600 3 g at 4 8C for 15 min.
The supernatant was harvested into ice-cold tubes and centrifuged at 10,000 3 g at 4 8C for 15
min. The detection range of PACAP38-LI for the tissue homogenates was between 16 and
1000 fmol/mL.Enzyme-linked immunoassay (ELISA)
We measured VIP-LI in the same plasma and milk samples as described for PACAP38-LI,
using a specific ELISA Kit (Sincere, Sincere Biotech Co., Ltd, Beijing, China) according to
the manufacturer’s protocol that is proven to be specific for ovine VIP. The reaction was
evaluated at an absorbance of 450 nm using a Multiskan RC microplate reader (Labsystems,
Thermo Scientific, Waltham, MA, USA). The optical density (OD) of the control wells was
subtracted from that of each sample and standard. The VIP concentration of the samples was
calculated using the standard curve. The detection range of the measurement was 7.8–500 pg/
mL, the sensitivity of the assay <2.0 pg/mL. The intra-assay and inter-assay precision of the
analysis were 8 and 12%, respectively.RNA extraction and primer design
Mammary gland samples stored in RNA Later (Sigma–Aldrich, St. Louis, MO, USA) were
homogenized in 1 mL of TRI Reagent (Molecular Research Centre Inc., Cincinnati, OH, USA)
and total RNA was isolated using the Direct-Zol RNA isolation kit (Zymo Research, Irvine,
CA, USA) according to the manufacturer’s instructions. The RNA samples were then treated
with 1 U DNase I (Zymo Research, Irvine, CA, USA) at 37 8C for 1 h, then quantified using a
NanoDrop1000 Spectrophotometer (Thermo Scientific, Bonn, Germany). One microgram RNA
(diluted in 10 mL nuclease-free water) was reverse transcribed into complementary DNA
(cDNA) using oligod(T)18 primers and the Maxima First Strand cDNA Synthesis Kit for RT-
qPCR (Thermo Scientific, Waltham, MA, USA) in 20 mL final volume, using an Eppendorf
Mastercycler DNA Engine Thermal Cycler PCR (Eppendorf Austria GmbH, Wien, Austria).
Primer pairs were designed with the primer design software of the National Center for
Biotechnology Information (www.ncbi.nlm.nih.gov/tools/primer-blast/). RT-qPCR primers and
product lengths for each gene are listed in Table 1 according to the revised COGNOSAC
guideline for the gene nomenclature in ruminants [17]. The specificities and amplification ef-
ficiencies of the primers were calculated using BLAST and the Stratagene Mx3000P QPCR
System (Agilent Technologies, Santa Clara, CA, USA). The efficiency values of the primers were
found to be as follows: b-actin: 102.4% (reference gene), PACAP: 92.6%, PAC1: 92.2%, BDNF:
80.8%, VIP primer number: 1: 89.6%, VIP primer number: 2: 80.3%. Primer efficiencies were
taken into account when calculating gene expression ratios [18].Unauthenticated | Downloaded 09/27/20 10:03 AM UTC
Table 1. Details of oligonucleotide primer sequences used in qPCR measurements
Gene
amplified Nucleotide sequence of primer
Primer
type
Number of base pairs
in DNA fragment
amplified (bp)
Nucleotide
range of primer
sequence
NCBI
reference
sequence
Beta-actin GCT GTG CTG TCC CTG TAC GC sense 459 498–956 NM_001009784.1
GCG GAT GTC GAC GTC ACA C antisense
PACAP AAATACTTGGCGGCTGTCCT sense 72 1030–1101 NM_001009776.1
GTACGGTATTCGCCGTCCTT antisense
PAC1 ACA GGC TGC TGG GAT ATG AAT G sense 251 1037–1287 XM_015095317.1
AGA GTA ATG GTG GAC AGT TCT G antisense
BDNF ACG AGA CCA AGT GCA ATC CC sense 102 915–1016 XM_004016359.2
GCA CGT ACG ACT GGG TAG TT antisense
VIP (1) AGG GAC CAA TCA AAC GCC AC sense 127 356–482 NM_001126368.1
GAC TCT CCT TCG CTG CTT CTC antisense
VIP (2) GCGTACTCTTCTCCCAGACC sense 73 50–122 NM_001126368.1
ATTCTGTCCCCCATCCTCAGA antisense
VPAC1 TCT TCT CCC CCA TTC AAG GC sense 145 384–528 XM_004018593.3
AAC ACT GTC TGC TGC TGC T antisense
VPAC2 TGT TCA GAC ATG AGA GTG GGT sense 150 2023–2152 XM_015095467.1
CTG AAT GCC GCT TGA GTC TT antisense
Abbreviations: PACAP 5 pituitary adenylate cyclase activating polypeptide; PAC1 5 pituitary adenylate cyclase activating polypeptide receptor 1;
BDNF 5 brain-derived neurotrophic factor; VIP 5 vasoactive intestinal peptide, VPAC1 5 vasoactive intestinal peptide receptor 1,
VPAC2 5 vasoactive intestinal peptide receptor 2.
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98 Physiology International 107 (2020) 1, 92–105Quantitative real-time polymerase chain reaction (qPCR) and data analysis
The reaction was set up in three technical replicates in a volume of 20 mL containing 20 ng
cDNA, 1 3 Luminaris Color HiGreen Low ROX qPCR Master Mix (ready-to use master mix
contains hot start Taq DNA polymerase in combination with an optimized buffer, Thermo
Scientific, Waltham, MA, USA), and 0.3 mM of each primer. Cycling conditions for amplifi-
cation were as follows: 95 8C for 10 min, followed by 40 cycles of 95 8C for 15 sec, 60 8C for 45
sec and 72 8C for 45 sec. The analysis was conducted using the Stratagene Mx3000P QPCR
System (Agilent Technologies, Santa Clara, CA, USA), equipped with a 96-well optical reaction
plate. The relative expression ratios were calculated using MxPro QPCR Software (Agilent
Technologies, Santa Clara, CA, USA) with ΔΔCt method, and normalized to b-actin as a
reference gene, showing stable expression in the mammary gland samples independently of age.
The samples of 3-month-old animals served as the control group. Product size was routinely
controlled by agarose gel electrophoresis. RNA samples without reverse transcription did not
give any amplification products with the primers used, indicating that genomic DNA
contamination was not present. PCR set-up of the VIP-specific semi-quantitative PCRFig. 1. PACAP38-like immunoreactivity (PACAP38-LI) determined by RIA (A) in the lamb plasma before,
as well as 1 and 2 h after suckling (n 5 9/group). PACAP38-LI in the mammary and jugular vein plasma in
comparison with milk whey of (B) 3-year-old mother ewes (n 5 8/group), (C) daily changes of PACAP38-
LI in the milk of lactating ewes (n 5 4/group) and (D) plasma PACAP38-LI in the jugular vein of the 3 age
groups (n 5 4/group). Statistical analysis: one-way ANOVA, Bonferroni’s post test. Results are shown as
means ± SEM, **P < 0.005, ***P < 0.0001. Abbreviations: mo: month, yr: years
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Physiology International 107 (2020) 1, 92–105 99measurement was conducted as described above. The PCR products were electrophoresed on a
2.5% agarose gel containing 0.01% GelRed (Biotium, Harward CA, USA) at 70 V for 40 min, and
visualized by Safe View (Cleaver Scientific Ltd, Warwickshire, UK) transilluminator (Supple-
mentary Fig. 1). The image acquisition was performed using the Vilber-Lourmat Bio-Profil
(version 97) gel documentation system with Bio-Capt Software (version 12.6).
Statistical analysis
All calculations were made by a licensed copy of GraphPad Prism 6.0. software (http://www.
graphpad.com/scientific-software/prism/, GraphPad Software Inc, La Jolla, CA). Data are
expressed as mean ± SEM. The normal distribution of data was tested using the Kolmogorov–
Smirnov test. In order to determine the statistical significance between 3 or more columns
analyzed altogether, one-way ANOVA followed by the Bonferroni’s post-test was used in all
cases. The Pearson rank correlation coefficient was used to compute the correlation between
PACAP, PAC1 receptor and BDNF mRNA expression in the mammary gland. In all cases, P <
0.05 was considered statistically significant.RESULTS AND DISCUSSION
Concentrations of PACAP38-LI in the plasma and milk of sheep
PACAP38-LI was approximately 20 fmol/mL in the plasma of lambs before suckling, which
showed an almost 2-fold increase (P < 0.001) 1 h later and returned to basal value 2 h after
suckling (Fig. 1A). There was no significant difference between PACAP38 levels obtained from
the jugular and mammary vein plasma samples (Fig. 1B). PACAP38 concentration in the milk
whey of ewes was about 10 times higher as compared to the plasma samples taken from the
jugular and mammary veins (P < 0.0001), but we did not detect changes in PACAP excretion in
milk during the daily cycle (Fig. 1C). Plasma PACAP38-LI concentrations were similar in the
three age groups (Fig. 1D).
Expression of PACAP mRNA and alteration of peptide levels in the mammary gland
The relative gene expression of PACAP was similar in all the three age groups (Fig. 2A).
PACAP38-LI showed an apparent trend to increase in the 3-year-old ewes (lambs vs. 3-year-old
group, P 5 0.075) and in the 10-year-old group (lambs vs. 10-year-old ewes, P 5 0.196), but
showed individual differences (Fig. 2B). In comparison, the PACAP-related peptide, VIP was
not expressed in the mammary gland of any age group, as shown by the lack of the presence of
its mRNA measured by semi-quantitative PCR (Supplementary Fig. 2, lower panel). The validity
of our method was confirmed by the detection of VIP transcripts with both sets of primers in all
age groups in the sheep uterus, as a positive control (Supplementary Fig. 2 upper panel).
Age-related PAC1 receptor and BDNF mRNA expressions and alterations in the
mammary gland
The expression of PAC1 receptor mRNA followed a gradually increasing tendency without any
significant differences between the lambs, 3-year-old and 10-year-old sheep (Fig. 3A). BDNFUnauthenticated | Downloaded 09/27/20 10:03 AM UTC
Fig. 2. Relative gene expression ratio of (A) PACAP and (B) PACAP38-LI of 3-month- (mo), 3-year- (3 yr)
and 10-year-old (10 yr) sheep mammary gland samples (n 5 4/group). Statistical analysis: one-way
ANOVA, Bonferroni's post test. Results are shown as means ± SEM.
100 Physiology International 107 (2020) 1, 92–105decreased with age: the mRNA levels were strongly down-regulated by 30% (P < 0.0001) and
60% (P < 0.0001) in 3- and 10-year-old sheep, respectively, as compared to lambs (Fig. 3B).
However, no correlation was found between BDNF and PACAP or PAC1 gene expression ratios
in any age group (data not shown, Pearson rank correlation coefficient). VPAC1/VPAC2 mRNA
could not be detected either in the udder or in the uterus tissues using the primers exclusively
available for sheep shown in Table 1.Unauthenticated | Downloaded 09/27/20 10:03 AM UTC
Fig. 3. Relative gene expression ratios of (A) PAC1 and (B) BDNF measured from mammary gland tissue
samples of 3-month- (3 mo), 3-year- (3 yr) and 10-year-old (10 yr) female sheep (n 5 4/group). Statistical
analysis: one-way ANOVA, Bonferroni's post test. Results are shown as means ± SEM, ***P < 0.0001.
Physiology International 107 (2020) 1, 92–105 101No change of VIP concentration in the plasma and milk in lactating ewes and lambs
VIP concentration in suckling lambs was approximately 20 pg/mL in lambs before suckling and,
in contrast to PACAP, it did not change either 1 h or 2 h after suckling (Fig. 4A). In lactating
ewes, we measured almost 2-fold higher peptide concentration in the milk whey compared to
mammary and jugular vein plasma samples (P 5 0.0004 and P 5 0.0027 respectively, Fig. 4B).
Plasma VIP content was not altered during aging, it was similar in the 3-month-old lambs, 3-
year- and in 10-year-old sheep (Fig. 4C).Unauthenticated | Downloaded 09/27/20 10:03 AM UTC
Fig. 4. VIP-like immunoreactivity measured by ELISA (A) in the lamb plasma before, as well as 1 and 2 h
after suckling (n 5 9), in comparison with milk whey of (B) 3-year-old mother ewes (n 5 8) and (C)
plasma VIP-LI in the jugular vein of the 3 age groups (n 5 4/group). Statistical analysis: one-way ANOVA,
Bonferroni's post test. Results are shown as means ± SEM, **P < 0.005, ***P < 0.0001. Abbreviations: mo:
months, yr: years
102 Physiology International 107 (2020) 1, 92–105
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We provide here the first evidence for the expression of PACAP38, but not the related peptide
VIP, in the mammary gland of lactating ewes, its high concentration in the milk independently
of the daily cycle, and its rapid increase in the lamb plasma 1 h after suckling.
Our previous measurements revealed that both fresh and pasteurized cow milk as well as cow
milk-based formulas contain the same amount of PACAP as human milk [9–11]. In human
milk, the peptide is present at a constantly high level until 10 months after delivery and increases
thereafter [9]. Its level does not differ in foremilk compared to hindmilk during suckling [10].
Although the source of PACAP in the milk is not known, we showed significantly increased
plasma PACAP concentration 1 h after suckling, which decreased close to the basal level 2 h
later. Despite the lack of available data in the literature, the explanation for our findings might
be a rapid absorption of PACAP38 from the milk in the proximal part of the gastrointestinal
tract in lambs and/or suckling-induced PACAP release from the brain or peripheral tissues.
Although we did not find any difference in plasma PACAP38-LI between the jugular and
mammary veins, we found an increasing tendency of PACAP mRNA expression in the
mammary gland of 3-year- and 10-year-old ewes. We propose that the high PACAP content of
the milk is likely to be derived from the plasma or locally released from the mammary gland.
Regarding the potential role of PACAP in the milk, it can directly act on the infant intestinal
tract and/or influence the development and maturation of different organs [19–22]. Moreover,
PACAP can also affect development, growth and hormonal activity of the mammary gland
itself [9].
It has been described that during lactation, VIP plays a role as a potent prolactin-releasing
factor in the pituitary in a paracrine and/or autocrine manner. We detected high amounts of VIP
in sheep milk whey compared to the plasma, similarly to previous findings in human milk [23,24].
We also showed the lack of VIP-specific mRNA in the udder in sheep, in accordance with former
observations in rats [23]. Based on our data, we propose that the VIP content of milk is derived
from the maternal circulation. Furthermore, besides VIP, we did not detect any specific mRNA in
these samples for VPAC 1/2 receptors either. However, this result may be due to technical issues,
since there are only predicted and partial coding sequences for the sheep VPACR 1/2 available in
the databases, and it is possible that this record does not have all the necessary start or stop se-
quences. VIP expression in the hypothalamus was shown to be regulated by estrogens in female
rats [25], which suggests that VIP might be altered by the peripherial estrogen-dependent con-
dition in the sheep. We investigated the age-dependent VIP level in the plasma, but did not detect
any differences between sexually immature lambs, mature young or old adult ewes.
It isknownthatPACAPandVIPregulatetheexpressionandactionsof theBDNFneurotrophicfactor
in theCNS. This neurotrophin has also been implicated in non-neuronal tissues [26], but its role has not
been clarified. Our results are consistent with previous data [14] where strong expression of BDNF was
foundin lambsandinmaturesheepbefore lambing,butgraduallydecreasingexpressionduring lactation.
WeobservedsignificantBDNFmRNAdown-regulationboth in3-and10-year-oldsheep,but therewere
no correlations between BDNF and either PACAP or PAC1 receptor gene expression.
The major novelty of the present study is that we provide the first data for a rapid increase of
PACAP38 in the lamb plasma after suckling with the help of highly sensitive and specific
analytical methods. The limitation of the results is that the source and the role of PACAP is not
possible to experimentally access in small ruminants, therefore only a hypothesis can beUnauthenticated | Downloaded 09/27/20 10:03 AM UTC
104 Physiology International 107 (2020) 1, 92–105suggested. However, the present results clearly open new perspectives for elucidating the
function of PACAP in the developing newborns, as well as a local role in the mammary gland.ACKNOWLEDGEMENT
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